← Alle Unternehmen
Über das Unternehmen
More than 50% of patients with cancer do not respond to the drug given to them. We developed a personalized, ex-vivo, single-cell method that can test 120+ drugs in parallel on a patient's live cancer and healthy cells. The test can identify which drugs and combinations are most effective for this patient, helping oncologists make better treatment decisions. Clinical trials consistently demonstrate that patients whose treatment was guided by our platform achieve significantly longer overall survival compared to those receiving the standard of care.